Fv-Hsp72

Fv-Hsp72 is a recombinant fusion protein designed to deliver heat shock protein 72 (Hsp72) directly into damaged or stressed cells. The drug consists of a single-chain variable fragment (Fv) derived from the monoclonal antibody 3E10 fused to human Hsp72. The 3E10-Fv component enables cell penetration by binding extracellular DNA and entering cells via the equilibrative nucleoside transporter 2 (ENT2), which is upregulated in tissues undergoing damage. Once inside the cell, Hsp72 acts as a molecular chaperone that prevents protein misfolding and aggregation, inhibits multiple apoptotic pathways (including Apaf-1 apoptosome formation, AIF-mediated apoptosis, and NF-κB signaling), reduces oxidative stress, and promotes cytoprotection[1][2][4]. Preclinical studies have shown that administration of Fv-HSP72 at reperfusion significantly reduces myocardial apoptosis and improves cardiac function following ischemia-reperfusion injury in animal models[2][3]. It has also demonstrated neuroprotective effects in models of traumatic brain injury by rapidly delivering Hsp72 to prevent secondary cell death[5]. Developed primarily for acute indications such as myocardial infarction and traumatic brain injury, Fv-Hsp72 represents a novel approach for direct intracellular delivery of cytoprotective proteins.

Brand names

Rapid Recovery

Other names

Rapid Recovery drug technology